PubRank

J Leibovici

Author PubWeight™ 29.29‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effects of high-molecular levan on the growth and spread of lymphoma in AKR mice. Cancer Res 1975 0.89
2 Suppression of humoral immune response in mice by administration of high molecular levan. Experientia 1978 0.88
3 Direct antitumor effect of high-molecular-weight levan on Lewis lung carcinoma cells in mice. J Natl Cancer Inst 1980 0.86
4 Effects of route and schedule of administration of high-molecular levan on the growth of AKR lymphoma. Cancer Res 1976 0.83
5 Macrophage-recognized molecules of apoptotic cells are expressed at higher levels in AKR lymphoma of aged as compared to young mice. Adv Exp Med Biol 2000 0.83
6 Effect of levan on the stages of development of experimental allergic encephalomyelitis. Isr J Med Sci 1976 0.81
7 A model for cancer treatment in advanced compared to early cancer. Anticancer Res 1987 0.81
8 The role of macrophages and polymorphs in the levan-induced inhibition of Lewis lung carcinoma in C57BL mice. Br J Cancer 1979 0.81
9 Animal models for tumor progression (short review). Anticancer Res 1984 0.81
10 Effect of native levan on homograft rejection in mice. Proc Soc Exp Biol Med 1975 0.81
11 Inhibition of 3LL carcinoma of mice by levan treatment. Isr J Med Sci 1977 0.80
12 Different biological behavior of AKR lymphoma cells from primary and metastatic tumors. Experientia 1985 0.80
13 Inhibitory effeft of oxidized spermine on the multiplication of coliphage T5. J Mol Biol 1966 0.80
14 Metastatic potential and multidrug resistance correlation in the B16 melanoma system. J Exp Ther Oncol 1996 0.80
15 Histological criteria for immunological rejection of mouse skin homografts. J Pathol 1977 0.79
16 Mechanism of the inhibitory effect of levan on experimental tumors. Recent Results Cancer Res 1980 0.79
17 Comparison of growth rate of two B16 melanomas differing in metastatic potential in young versus middle-aged mice. Cancer Invest 1997 0.79
18 Serial passage of tumors in mice in the study of tumor progression and testing of antineoplastic drugs. Cancer Res 1984 0.79
19 Spontaneous AKR lymphomas differ in their degree of malignancy and sensitivity to the polysaccharide levan. Experientia 1983 0.79
20 Role of immune response as determinant of tumor progression in function of host age in the B16 melanoma. Mech Ageing Dev 1995 0.78
21 Augmentative effects of intracellular chemotherapy penetration combined with hyperthermia in human ovarian cancer cells lines. Gynecol Oncol 1994 0.78
22 Antiphage action of oxidized polyamines. Isr J Med Sci 1965 0.78
23 Direct antitumor effect of the polysaccharide levan in mice: effects of drug concentration and time and temperature of incubation. J Natl Cancer Inst 1984 0.77
24 Effect of hyperthermia and thermochemotherapy on primary and metastatic tumour cells of AKR lymphoma. Int J Exp Pathol 1990 0.77
25 Malignant phenotype correlating with drug resistance in two human neuroblastoma cell lines. J Neurooncol 1994 0.77
26 [Properties of threonine deaminase from wild type and a valine sensitive mutant of Bacillus subtilis]. Bull Soc Chim Biol (Paris) 1969 0.77
27 Modification of the tuberculin reaction by levan. Br J Exp Pathol 1978 0.77
28 Histological changes in spleen and lymph nodes of mice administered cyclophosphamide and levan. Cell Tissue Res 1986 0.77
29 Increase in cell permeability to a cytotoxic agent by the polysaccharide levan. Cell Mol Biol 1985 0.77
30 Effect of splenectomy on treatment of Lewis lung carcinoma by an immunomodulatory polysaccharide and a cytotoxic agent. J Surg Oncol 1987 0.77
31 Comparison of splenectomy effects as an indication for host response to growth of primary and metastatic tumour cells in two murine tumour systems. Int J Exp Pathol 1995 0.77
32 Effect of splenectomy on the efficiency of chemo-immunotherapy of melanoma-bearing mice. Int J Immunopharmacol 1985 0.76
33 Effect of lectins on tumorigenicity of AKR lymphoma cells of varying malignancy. Anticancer Res 1987 0.76
34 Lysis and growth stimulation of a murine melanoma determined by density of macrophage populations. Anticancer Res 1985 0.76
35 Different effects of the polysaccharide levan on the oncogenicity of cells of two variants of Lewis lung carcinoma. Br J Exp Pathol 1986 0.75
36 Enhancing effect of ATP on intracellular adriamycin penetration in human ovarian cancer cell lines. Biochim Biophys Acta 1994 0.75
37 Combined effect of levan and cytotoxic agents on the growth of experimental tumours in mice. Br J Exp Pathol 1983 0.75
38 Change from inhibition to stimulation by levan of AKR lymphoma following serial transfers. Exp Cell Biol 1984 0.75
39 AKR lymphoma malignancy variants differing at late phase of metastasis. Cancer Lett 1990 0.75
40 Release from apoptosis correlates with tumor progression in the AKR lymphoma. Biochim Biophys Acta 2000 0.75
41 Apoptotic cell death and related gene expression in metastatic tumors of AKR lymphomas of varying malignancy. Apoptosis 1999 0.75
42 Biological behavior and cell properties of new AKR lymphoma malignancy variants. Tissue Cell 1998 0.75
43 [C. Influence of levan on the development of malignant tumors in mice]. Harefuah 1977 0.75
44 Enhancement of cytotoxic agent accumulation by Doppler flow sonication of human ovarian cancer cells. Eur J Gynaecol Oncol 1994 0.75
45 Effect of hyperthermia on AKR lymphoma variants differing in degree of malignancy. Cancer Invest 2001 0.75
46 Apoptosis and cell proliferation capacity in AKR lymphoma malignancy variants. Cancer Invest 2000 0.75
47 Cellular functions related to metastasis differing between low- and high-malignancy variants of AKR lymphoma. Pathobiology 1992 0.75
48 Apoptosis, cell proliferation and in vivo biological behaviour of primary and metastatic tumour cells of an AKR lymphoma variant. Apoptosis 1997 0.75
49 Effect of levan on tumorigenicity of cells from different murine tumors. Cell Mol Biol 1984 0.75
50 Metastasis-related cell functions in primary and metastatic tumor cells of AKR lymphoma. Cancer Lett 1996 0.75
51 Sensitivity to macrophages decreases with tumor progression in the AKR lymphoma. Adv Exp Med Biol 2000 0.75
52 Effect of local administration of levan on skin homograft rejection in mice. Proc Soc Exp Biol Med 1976 0.75
53 In vitro effect of levan-activated macrophages on Lewis lung carcinoma cells. Int J Immunopharmacol 1986 0.75
54 Combined treatment of Lewis lung carcinoma by tumor excision and levan. Oncology 1981 0.75
55 Metastasis-associated cell functions in AKR lymphoma malignancy variants. Invasion Metastasis 1995 0.75
56 Combined effect in vitro of chemotherapy with agents acting on the cell membrane of Lewis lung carcinoma. Chemotherapy 1990 0.75
57 Histological study of homografts showing delayed rejection following levan administration. J Pathol 1978 0.75
58 Effect of a membrane-active agent on uptake of adriamycin in Lewis lung carcinoma cells derived from 'primary' and 'metastatic' growths. Chemotherapy 1992 0.75
59 Changes in distribution of lectin receptors in macrophages activated by Nocardia water soluble molecules. Cell Mol Biol (Noisy-le-grand) 1993 0.75
60 Protective effect of native levan on endotoxin toxicity in mice and rats. Experientia 1979 0.75
61 Effect of tumor inhibitory and stimulatory doses of levan, alone and in combination with cyclophosphamide, on spleen and lymph nodes. Int J Immunopharmacol 1986 0.75
62 A model for the study of the long duration pathogenesis of cancer and its relevance to therapy. Med Hypotheses 1983 0.75
63 Bone marrow and peripheral blood modifications in C57BL mice administered with cyclophosphamide and levan. In Vivo 1992 0.75
64 Blood levels of high-molecular levan in mice as a function of the route and duration of administration. Arzneimittelforschung 1980 0.75
65 Slow cytotoxicity of the polysaccharide levan on tumor cells in vitro. Chem Biol Interact 1986 0.75
66 Inhibitory and stimulatory effects of levan on growth of B16 melanoma--possible mechanisms. Cell Mol Biol 1985 0.75
67 Drug resistance and its counteraction by cyclosporin A in function of metastatic potential in the Lewis lung carcinoma system. Cell Mol Biol (Noisy-le-grand) 1994 0.75
68 Opposite effects on tumor growth depending on dose of an immunomodulatory polysaccharide with or without cyclophosphamide. Anticancer Res 1985 0.75
69 Successful contact sensitization to chromate in mice. Int Arch Allergy Appl Immunol 1988 0.75
70 Effect of administration schedule on the levan-cyclophosphamide combined treatment of Lewis lung carcinoma. Int J Immunopharmacol 1983 0.75
71 Effect of levan on the fate of experimental hematogenous metastases of Lewis lung carcinoma. Exp Mol Pathol 1982 0.75
72 Different stages of tumor development are unequally affected by pretreatment of tumor cells with a polysaccharide. Cancer Lett 1984 0.75